Synchrony Bio

Synchrony Bio is a venture capital firm established in 2018 and located in Saint Louis, Missouri. It focuses on early-stage investments in the biomedical, medical device, and life science sectors. The firm aims to mitigate risk while enhancing value and efficiency in the development of its portfolio companies. By concentrating on innovative ventures, Synchrony Bio seeks to contribute to advancements in healthcare and technology.

Charles Bolten

Co-Founder & Managing Director

Past deals in Missouri

Journeys Metabolic

Seed Round in 2019
Readout is a digital health company with a mission to help patients better manage their own health by providing novel, clinically-backed tools to easily measure health biomarkers. Biosense was launched in early 2020 as a Class 1 medical device in the clinical, consumer, and research market after a successful clinical trial. As the only clinically-backed breath ketone measurement handheld device+app, Biosense provides full-day feedback of ketosis with unlimited measurements leading to protocol adherence and better outcomes. Biosense is used by obesity and diabetes clinics for in-home testing of ketosis, pharma and academic trials, as well as DTC via https://mybiosense.com.